Загрузка...
Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
BACKGROUND: The presence of hypoxia is a poor prognostic factor in prostate cancer and the hypoxic tumor microenvironment promotes radioresistance. There is potential for drug radiotherapy combinations to improve the therapeutic ratio. We aimed to investigate whether hypoxia-associated genes could b...
Сохранить в:
| Опубликовано в: : | BMC Urol |
|---|---|
| Главные авторы: | , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8247203/ https://ncbi.nlm.nih.gov/pubmed/34210300 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12894-021-00856-x |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|